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Abstract
Dendritic cells (DCs) are able in tissue culture to phagocytose and present antigens derived
from infected, malignant, and allogeneic cells. Here we show directly that DCs in situ take up
these types of cells after fluorescent labeling with carboxyfluorescein succinimidyl ester (CFSE)
and injection into mice. The injected cells include syngeneic splenocytes and tumor cell lines,
induced to undergo apoptosis ex vivo by exposure to osmotic shock, and allogeneic B cells
killed by NK cells in situ. The CFSE-labeled cells in each case are actively endocytosed by DCs
in vivo, but only the CD8 subset. After uptake, all of the phagocytic CD8 DCs can form
major histocompatibility complex class II–peptide complexes, as detected with a monoclonal
antibody specific for these complexes. The CD8 DCs also selectively present cell-associated
antigens to both CD4 and CD8 T cells. Similar events take place with cultured DCs; CD8
DCs again selectively take up and present dying cells. In contrast, both CD8 and CD8 DCs
phagocytose latex particles in culture, and both DC subsets present soluble ovalbumin captured
in vivo. Therefore CD8 DCs are specialized to capture dying cells, and this helps to explain
their selective ability to cross present cellular antigens to both CD4 and CD8 T cells.
Key words: dendritic cells • cross-presentation • apoptosis • dendritic cell subset • CD8
dendritic cell

Introduction
Dendritic cells (DCs)* are particularly efficient in the cross
presentation of antigens. DCs can present, on MHC class I
products, peptides derived from incoming immune complexes (1–3), heat shock proteins (4–6), nonreplicating bacteria (7), and dying cells (8–13). Dying cells are likely to be
an important source of antigen in many settings, for example, tumors, transplants, infections, and autoimmunity. To
understand the role of DCs in the presentation of cell-associated antigens, which occurs efficiently on both MHC class
I (8–13) and class II products (14, 15), we have directly
followed the capacity of DCs to take up dying cells in
vivo, particularly spleen cells labeled with carboxyfluorescein succinimidyl ester (CFSE). Injected splenocytes are

commonly used to follow the immune response to cell
associated antigens (16–18), and DCs are the principal cells
presenting these antigens onto MHC class I (19). We find
that uptake of several types of dying cells in situ occurs selectively in the CD8 subset of DCs. This is associated
with selective presentation on both MHC class I and II
products. In contrast, uptake of latex occurs to a comparable extent in both CD8 and CD8 DCs as reported (20).
We discuss the emerging evidence that subsets of DCs have
distinct endocytic receptors, a critical limiting variable for
implementing antigen presentation, and that one potential
consequence of apoptotic cell uptake is tolerance to cell
associated antigens.
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*Abbreviations used in this paper: CFSE, carboxyfluorescein succinimidyl
ester; DC, dendritic cell; RT, reverse transcription.

Materials and Methods
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Mice. C57BL/6, (BALB/c  DBA/2) F1 (CD2F1), CBA/J,
and BALB/c mice were purchased from Japan SLC or Nippon
Clea. TCR transgenic mice were specific for OVA presented on
H-2Kb or I-Ab (CD8 OT-I and CD4 OT-II; provided by Dr.
F. Carbone, University of Melbourne, Parkville, Victoria, Aus-

J. Exp. Med.  The Rockefeller University Press • 0022-1007/2002/05/1289/14 $5.00
Volume 195, Number 10, May 20, 2002 1289–1302
http://www.jem.org/cgi/doi/10.1084/jem.20020161

Downloaded from http://rupress.org/jem/article-pdf/195/10/1289/984051/jem195101289.pdf by Rockefeller University user on 11 August 2020

of Animal Development and Physiology, Graduate School of Biostudies, and 2Department of Zoology,
Graduate School of Science, Kyoto University, Kyoto 606-8502, Japan
3Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021

1290

PI and annexin, and 17% were PI and annexin, within 3 h of
culture at 37 C, whereas only 5 and 6% of untreated cells became
PI annexin and PI annexin, respectively.
For NK cell depletion, mice were injected intraperitoneally
with 50 l of rabbit anti–mouse asialo-GM1 serum (Wako Pure
Chemical Industries Ltd.) 3 and 1 d before injecting CFSE-labeled
B cells. Control mice were injected with normal rabbit serum.
In Vivo Uptake of FITC-Latex Microspheres or CFSE-labeled Cells
by DCs. Three mice/group were injected with 200 l of 0.27%
1 m Fluoresbrite™ Yellow Green Carboxylate Microspheres
(FITC-Lx; Polysciences, Inc.) or 1–2  107 CFSE-labeled cells
intravenously. The mice were killed at various time points, and
FITC- or CFSE-labeled cells were analyzed in the CD11c fraction by FACS®, or by deconvolution microscopy (Olympus) after sorting with an EPICS ALTRA® flow cytometer as above.
In Vitro Uptake of FITC-Latex Microspheres or CFSE-labeled Cells
by DCs. After staining with PE-CD8 or PE-CD11b mAbs,
enriched CD11c DCs at 105 cells/well were seeded in triplicate
with a final concentration of 0.0027% (vol/vol) FITC-Lx or
graded doses of CFSE-labeled, osmotically shocked B cells in 0.2
ml of RPMI 1640 supplemented with 5% FCS, 50 M 2-mercaptoethanol, 100 g/ml streptomycin, and 100 U/ml penicillin
in 96-well flat-bottomed plates, and then cultured for 1–12 h in a
CO2 incubator. Controls were incubated at 4 C. The percentage
of phagocytic DCs in each subset was calculated by subtracting
the value of the control from the experimental culture.
Flow Cytometric Analyses. Low density spleen, lymph node,
and liver leukocytes were depleted of CD3, Gr-1, and B220expressing cells and stained with PE-CD11c in combination with
biotinylated mAbs plus streptavidin-Red670 or -CyChrome®.
Cells were incubated before staining with 2.4G2 mAb on ice for
30 min to prevent nonspecific mAb binding. All procedures were
performed using cold PBS containing 5 mM EDTA, 0.02%
NaN3, and 1% FCS. DCs were acquired as CD11c cells. Surface
antigen expression was monitored on a FACSCalibur™ and analyzed with CELLQuest™ program (Becton Dickinson) or WinMDI software (TSRI). For cytoplasmic staining, the cells stained
with PE-CD11c were fixed with 4% (wt/vol) paraformaldehyde
for 30 min on ice, permeabilized with 0.1% saponin, and incubated with biotinylated mAbs and Avidine-Red 670. For 4-color
staining, the cells were stained with PE-CD11c and APC-CD8
followed by biotinylated mAbs and Streptavidin-CyChrome®.
Immunofluorescence Microscopy. Spleen samples were embedded in Tissue-Tek® OTC (Sakura Fine Technical Co., Ltd.) and
stored at –20 until use. Cryosections at 10 m of thickness were
fixed with acetone for 10 min, and then incubated successively
with SER-4 anti-CD169, Cy3-conjugated F(ab)2 mouse anti–rat
IgG, rat IgG for blocking, biotin-CD11c or CD8, and streptavidin-Cy5. Purified DCs were adhered to poly-l-lysine-coated
glass coverslips for 1 h in a CO2 incubator. The cells were then
fixed in 3% (wt/vol) paraformaldehyde followed by permeabilization with 0.05% saponin in RPMI 1640 containing 10 mM
HEPES and 10% FCS, and then stained for CD205 or CD107b
using Cy5-conjugated F(ab)2 mouse anti–rat IgG followed by
biotin-anti-I-Ab and streptavidin-Cy3. After washing, specimens
were mounted with glycerin-PBS (1:1) containing 1% propylgallate (Wako Pure Chemicals Industries, Ltd.)
Stimulation of TCR Transgenic T Cells to Monitor Antigen Presentation. The experiments used mice injected with C57BL/6
splenocytes or EL-4 tumor cells that had been osmotically
shocked in 10 mg/ml OVA, or mice injected with I-E allogeneic BALB/c B cells. After allowing uptake to take place in situ,
the DCs were added to T cells from TCR transgenic mice
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tralia) or specific for I-E presented on I-Ab (CD4 1H3 T cells;
provided by C. Viret and C.A. Janeway, Jr., Yale University,
New Haven, CT). DEC-205 (CD205)-deficient mice were made
and provided by M. Nussenzweig (Rockefeller University, New
York, NY). The mice were maintained under specific pathogen
free conditions and used at 7–8 wk of age. All experiments were
conducted according to institutional guidelines.
Antibodies and Reagents. Rat mAbs for MHC class II
(TIB120, M5/114.15.2), CD205 (HB290, DEC-205), granulocytes (RB6–8C5: Gr-1), B220 (TIB146: RA3–3A1, RA3–6B2),
F4/80 (HB198), and CD8 (TIB211, 3.155) were from American
Type Culture Collection. FITC-anti-CD11c, CD3, Thy-1.2
(CD90), B220 and CD107b, PE-conjugated anti-CD8, CD11b,
CD11c, biotinylated anti-CD4, CD8, I-Ab, CD40, CD54, CD80,
CD86 and CD11c, mouse anti–human V8, and streptavidinCyChrome® were from BD PharMingen. Y-Ae mAb, specific
for the MHC–peptide complex formed by I-Ab presenting a peptide from I-E (14, 21), was provided by Dr. C.A. Janeway, Jr.
Anti-CD11c, CD43, CD19, and CD5 microbeads® were from
Miltenyi Biotec. The other reagents were rat IgG, FITC-conjugated mouse anti–rat IgG, biotin-conjugated rat IgG, biotinconjugated Syrian hamster IgG, Cy3-conjugated F(ab)2 mouse
anti–rat IgG, Cy3-conjugated F(ab)2 goat anti–rat IgG, streptavidin-Cy5 and streptavidin-Cy-3 (Jackson ImmunoResearch Laboratories), biotin-conjugated anti-CD11b and F4/80 (Caltag
Labs), allophycocyanin (APC)-conjugated anti-CD8 and CD11b
(eBioscience), collagenase D (Boehringer), Percoll (Amersham
Pharmacia Biotech), RPMI 1640 (Nissui Pharmaceutical Co.
Ltd.), 30% BSA solution (Sigma-Aldrich), and avidin-Red670™
(Life Technologies).
Cell Preparations. DCs from spleen and subcutaneous lymph
nodes were positively selected (anti-CD11c microbeads®) from
low density cells as described (22). In some experiments, the
CD8 DCs subset was first positively enriched with anti-CD8
microbeads® from spleen low-density cells, depleted of T cells by
either CD3 or CD90, B cells by either CD19 or B220, and
granulocytes by Gr-1; then CD8, CD11c DCs were purified
by anti-CD11c microbeads® from the remaining cells. In other
experiments, CD8 and CD8 DCs were purified by sorting
with EPICS ALTRA® flow cytometer (Beckman Coulter) after
preenrichment of CD11c DCs by Microbeads®. Liver DCs
were prepared from collagenase-digested livers enriched for leukocytes on Percoll gradients, followed by the depletion of CD3,
B220, and Gr-1-expressing cells as described (23). In liver, low
and high CD11b expression is preferable for identifying DC subsets, because CD8 expression is lower than in spleen (23).
B cells were negatively selected CD43 cells (anti-CD43 microbeads®) from spleen suspensions. In some experiments, B cells
were activated with goat F(ab)2 anti–mouse IgM/IgG plus IL-4
for 2 d as described (14). TCR-transgenic, CD8 OT-I T cells
were prepared by depleting B220, Gr-1, CD4, F4/80, MHC class
II, and NK1.1-expressing cells using sheep anti–rat IgG Dynabeads®. For CD4 OT-II and 1H3 T cells, anti-CD8 instead of
CD4 mAb was used. Macrophages were peritoneal exudate cells
of mice that had been injected with 2 ml of thioglycollate medium 4 d before.
To label with CFSE (Molecular Probes), B cells or the BaF3
and EL-4 cell lines were suspended at 107/ml in RPMI and incubated with CFSE at concentrations of 5 M for in vivo injection
and 1 M for in vitro assay for 10 min at 37 C. The reaction was
stopped by washing three times with PBS-0.1% BSA. CFSElabeled cells were osmotically shocked (16–18) to accelerate apoptosis. By this treatment, 55% of the cells were stained with both

Results
Both CD8 and CD8 splenic DCs phagocytose latex in
vivo, but only CD8 DCs take up injected apoptotic splenocytes. Following on the work of Shortman and colleagues that splenic DCs phagocytose latex beads administered intravenously (20), we injected mice with either 1
micron FITC-modified latex spheres or CFSE-labeled
splenocytes. The latter were subject to osmotic shock,
which is used to load splenocytes with exogenous proteins
like OVA (16–18). We found that apoptosis, as assessed by
FITC-annexin staining, was induced in the majority of
splenocytes within 3 h of an osmotic shock delivered ex
vivo (not shown). 1 h after injecting CFSE-labeled osmotically shocked splenocytes, or FITC-latex, we enriched
DCs from the spleens on the basis of their low buoyant
density (22). Then flow cytometry with antibodies to
1291
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CD11c and CD8 was used to identify the low density cells
that had taken up CFSE-splenocytes or FITC-latex.
Fig. 1 A (left) shows that both CD8 and CD8 DCs
took up latex as described (20), primarily one bead but
occasionally two beads per cell (arrows). However only
CD8 cells endocytosed CFSE-labeled apoptotic splenocytes, either syngeneic or allogeneic (arrows, Fig. 1 A
right). Very few CFSE-labeled cells were noted in the
CD11c low density cells, or the high density fraction (not
shown), and these were not further characterized. Fig. 1 B
describes the phenotype of the phagocytic DCs in the
CD11c low density population. Staining for the lysosomal
marker lamp 2 (CD107b) was weak, in contrast to macrophages. The CD68 and 2A1 antigens, found within small
numbers of endocytic vacuoles of DCs (24), were expressed
by phagocytic DCs, but the MIDC-8 marker of T cell area
DCs (25) was lacking. In the case of latex, only some of the
phagocytic cells expressed DEC-205/CD205; however, the
DCs capturing apoptotic splenocytes had a high level of
DEC-205 (Fig. 2 B) and low levels of CD11b (not shown),
as expected for the CD8 subset (26, 27). Therefore, uptake of particulates in vivo by splenic DCs is influenced by
the particle. Only CD8 DCs take up apoptotic splenocytes, whereas both CD8 and CD8 DCs take up latex.
Selective Uptake of Allogeneic B Cells, Killed by Recipient
NK Cells, by CD8 DCs. Fig. 2 compares the uptake in
vivo of live syngeneic versus allogeneic CFSE-labeled B
cells by C57BL/6 splenic DCs. CD43-negative resting B
cells were used instead of splenocytes to avoid the induction of graft versus host disease by allogeneic T cells. The
injected cells, which labeled at a high level for CFSE (Fig. 2
A, white arrows), carried B cell markers and were abundant
in the DC-depleted high density population of spleen (not
shown). Fig. 2 A (middle) shows that syngeneic live cells
were for the most part ignored, but allogeneic cells were
again captured by CD8 DCs (Fig. 2 B, black arrowhead).
Fig. 2 B (arrows) shows that CFSE-labeled allogeneic B
cells were captured by the CD8 subset of DCs in spleen,
lymph node, and liver. The kinetics of uptake of CFSElabeled cells were then followed using both live and apoptotic (osmotic shock) allogeneic B cells. DC uptake of live
cells increased with time, so that at 12 h, 20–30% of the
splenic and lymph node DCs had strong CFSE labeling
(Fig. 2 C, filled symbols). In contrast, if apoptotic cells were
injected, the kinetics of uptake were different. The DCs
from spleen and liver became labeled within an hour, but
labeling was decreased at later time points and no labeling
was found in lymph node DCs (Fig. 2 C, open symbols).
These findings raised the hypothesis that the allogeneic B
cells were being killed before efficient uptake by DCs in all
organs through which the B cells were recirculating.
Fossum et al. had years ago described the rapid clearance
of allogeneic leukocytes after NK dependent killing in vivo
and had visualized uptake of injected cell fragments by DCs
in tissue sections through the T cell areas (28). The lytic activity of NK cells is activated by “missing self” (29), as
would occur when allogeneic B cells lacking “self MHC”
are injected. We tested if treatment of recipient mice with
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(above) to assess presentation of the captured and processed antigens (see legends).
Reverse Transcription PCR. Total RNA was extracted from 106
sorted CD8 and CD8 spleen DCs and peritoneal macrophages
using TRIzol Reagent (GIBCO BRL) and used to produce
cDNA template with SuperScript II (GIBCO BRL) in accordance with manufacturer’s protocols. The cDNA was then used
in reverse transcription (RT)-PCR with Z-Taq DNA polymerase (Takara Shuzo). The primers were: for integrin v (5CAA GCT CAC TCC CAT CAC-3, 5-GGG TGT CTT
GAT TCT CAA AGG G-3), integrin 3 (5-TTG CTA CTC
TGC TCA TCT GGA AGC-3, 5-TCC CCA CAC TCG
TCA CAC ACA TAAG-3), integrin 5A (5-TTG CCA AGT
TCC AAA GTG A-3, 5-GCG TGA CCT TTT TAT TTC
AT-3), integrin 5B (5-TGC CAA GTT CCA AAG CCT-3,
5-GCG TGA CCT TTT TAT TTC AT-3), CD14 (5-TTT
TGG ACT CTG AAT CCC ACT CGG-3, 5-TAC CCA
CTG AAC CAT CTT GAC TGC C-3), CD36 (5-CAG CCC
AAT GGA GCC ATC-3, 5-CAG CGT AGA TAG ACC
TGC-3), scavenger receptor class BI (5-CAT CTG GTG GAC
AAA TGG AAC G-3, 5-CGT GGG AAT GCC TTC AAA
CAC-3), macrophage scavenger receptor type I (SR-AI; 5ACA GTT CGA CTG GTT GGT GGT AGT G-3, 5-TGA
AGT ACA AGT GAC CCC AGC ATC-3), macrophage scavenger receptor type II (SR-AII; 5-CAC CTC TGG ACA AGT
CAT CAA CAC-3, 5-GAA GGC AGG AAC ATC CCT
CTA CTC-3), C1q receptor (5-GAC ACC TCA CCC CAG
CCA TCT G-3, 5-CAC TGA GTG GTA CAG AAT GGC
AC-3), phosphatidylserine receptor (PtdsR; 5-CAT CAA GGT
GAC CCG AGA AGA AGG-3, 5-AAG TTG GTG CTG
CTG GCA AAG TTC-3), CD68 (5-ATG CGG CTC CCT
GTG TGT C-3, 5-TCA GAG GGG CTG GTA GGT TG3), CD4 (5-GAG AGT CAG CGG AGT TCT C-3, 5-CTC
ACA GGT CAA AGT ATT GTT G-3), CD23 (5-GGA
ACTG CAT GCA ACA TAT GTC CCA AGA ACT GGCT3, 5-GTC AGG GTT CAC TTT TTG GGG TGG GCC T-3),
mDC-SIGN (5-ACA TGA GTG ATT CTA AGG AAA TGG3, 5-TGT CAA GGT TAT CAA TGG TCA CAG-3), and
actin (5-CAG GAG ATG GCC ACT GCC GCA-3, 5-CTC
CTT CTG CAT CCT GTC AGC A-3). Amplification was begun at 95 C for 2 min followed by 30 cycles (each cycle being
98 C for 1 s, 60 C for 5 s but 68 C for -actin, and 72 C for 5 s)
and a final extension of 70 C for 7 min.

Figure 2. Allogeneic B cells are selectively captured by CD8 splenic DCs. (A) Dot plots of the low density spleen population 12 h after injecting mice
with PBS or 20  106 live syngeneic or allogeneic B cells. In the left vertical column, CD11c DCs are arrowed and contain CD8 and CD8 subsets.
In the right vertical column, the uptake of allogeneic B cells by CD8 DCs is evident (black arrowhead), as are some of the injected strongly CFSE-positive living B cells (white arrows). 1.3% of low density cells were phagocytic for allogeneic B cells. (B) Uptake of CFSE-labeled allogeneic B cells by
CD8 DCs from spleen and subcutaneous lymph nodes, and CD11b low liver DCs (reference 23), 12 h after injection. Panels of dot plot showed
CD11c cells, and phagocytic cells in spleen, lymph nodes, and liver were 4.5, 6.6, and 2.5%, respectively. (C) Kinetics of uptake of allogeneic live B
cells, or apoptotic osmotically shocked B cells, by DCs in three organs. Uptake at early time points may result from B cell killing in blood, and at later
time points, killing of B cells within lymphoid tissues in which the B cells recirculate. The percentage of phagocytic DCs are shown for CD8 DCs in
spleen and lymph nodes and CD11blow cells in liver.
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Figure 1. Apoptotic B cells
and splenocytes, but not FITClatex spheres, are selectively captured by CD8 splenic DCs in
vivo. (A) Groups of three mice
were injected with PBS, FITClatex (0.2 ml of a 0.27% solution), or 20  106 apoptotic
CFSE-labeled syngeneic or allogeneic B cells. 1 h later, splenic
suspensions were floated in dense
BSA to provide DC-enriched
low density cells (reference 22).
The latter were stained for
CD11c and CD8 and examined
by FACS® (see also Fig. 2 A).
Shown here are cells gated for
CD11c expression and analyzed
for PE–anti-CD8 and fluorescein stain. Phagocytic DCs are
arrowed. The percentage of
phagocytic CD8 and CD8
DCs for FITC-Lx was 2.7 and
3.8% of total CD11c cells, respectively. Comparable percentages (1.5%) of DCs were capable
of phagocytosing apoptotic syngeneic and allogeneic B cells.
(B) DCs that phagocytose
FITC-latex (5.7%) and CFSE-apoptotic splenocytes (1.45%) are comparable in phenotype (panel numbers are mean fluorescence in arbitrary units), except for higher DEC-205 endocytic receptor on those DCs taking up splenocytes (lower right).

CD11c DCs in situ whereas uptake of cells induced to apoptose ex vivo is extensive in DCs in the red pulp as well as
some marginal zone macrophages.
CD8 DCs Also Selectively Take Up Apoptotic Tumor Cells
Administered Intravenously. We induced apoptosis of different cell lines either by withdrawing an essential cytokine
(nontransformed BaF3 cells; Fig. 5 A), or by applying osmotic shock or high doses (50–300 Gy) of ionizing irradiation (tumorigenic EL-4 cells, Fig. 5 B). The cell lines were
then injected intravenously, and recipient spleen cells examined for the capture of CFSE-labeled cells. Again, only the
CD8 DC subset took up the injected cells, and only when
cell death had been initiated ex vivo (arrows, Fig. 5 B). As
DEC-205 is an endocytic receptor expressed at high levels
on CD8 DCs, we also tested uptake in DEC-205/
mice. However, no defect was noted in DC phagocytosis in
the absence of DEC-205 (Fig. 5 A). In summary, the CD8
DC subset selectively captures dying cell lines in vivo.
Single Cell Assays to Verify Formation of MHC–Peptide
Complexes from Phagocytosed Dying Cells In Situ. To monitor the processing of cell-associated antigens into MHC–
peptide complexes, we extended a prior tissue culture study
(14) using the Y-Ae monoclonal antibody that is specific
for I-Ab molecules presenting a peptide from another
MHC product, I-E (21). In keeping with the prior work
(14), CFSE-labeled, allogeneic I-E B cells from BALB/c
mice were injected into I-Ab C57BL/6 mice. 12 h later,
CD8 and CD11c DCs contained most of the phagocytosed CFSE labeled cells in the spleen cell suspension (Fig.
6 A), and virtually all the CFSE-labeled DCs stained for
Y-Ae above the background observed with control mouse
IgG (Fig. 6 B, right). Y-Ae staining could not be detected
in mice given syngeneic B cells or no B cells (Fig. 6 B,
right). The phagocytic DCs had higher levels of MHC class
II than the nonphagocytic DCs (mean fluorescence index
of 590.5 vs. 251.3 in Fig. 6 B, bottom row), but this high
MHC class II subset was clearly evident in the nonphago-

Figure 3. Recipient NK cells
are required for DCs to take up
allogeneic B cells. C57BL6 mice
were treated with control antiserum or rabbit anti-asialoGM1,
the latter to deplete NK cells
(references 30 and 31). Then
CSFE-labeled 10  106 allogeneic (BALB/C) or syngeneic B
cells (A), or 20  106 allogeneic (DBA/2) or semiallogeneic
(C57BL6  DBA/2 F1)(B) were
injected intravenously 12 h later,
low density splenocytes were
isolated, stained for CD11c and
CD8, and the percentage of
CFSE-labeled CD11c DC subsets (CD8 and CD8 determined by FACS®.
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the NK depleting asialoGM antibody (30, 31) would block
the uptake of CFSE-labeled allogeneic splenocytes by DCs.
The anti-asialoGM antibody did not deplete T cells or B
cells, but splenic CD3 NK-1.1 cells were reduced from
3–4% to 0.1% by this treatment (data not shown). The
treatment nullified the capacity of DCs in spleen and
lymph node to capture injected allogeneic splenocytes (Fig.
3, A and B). As expected for NK-mediated killing, semiallogeneic B cells were captured much less efficiently than
fully allogeneic ones (Fig. 3 B). Therefore, live allogeneic
cells, probably after killing by NK cells, were efficiently
phagocytosed by CD8 DCs; this provided an efficient
model to further characterize DCs that take up cell associated antigens in situ.
Identification of Phagocytic DCs in Sections of Spleen. We
first looked in sections for the injected live, CFSE-labeled
allogeneic B cells. Most were found in the B cell areas (follicles) of spleen white pulp and lymph node, as expected
(Fig. 4 A). We occasionally detected cells taking up CFSElabeled cells within numerous macrophages of the marginal
zone, but we readily found CFSE-phagosomes within
CD11c DCs in the T cell areas as well as the red pulp region (Fig. 4, B and C; white arrows). In contrast, when
FITC latex was injected, we observed extensive uptake at
1 h into CD8CD11c DCs in the red pulp (Fig. 4, D and
E, white arrows), CD169 (sialoadhesin) marginal zone
metallophil macrophages (Fig. 4 E, white arrowheads), as
well as CD169 or low marginal zone macrophages (Fig. 4, D
and E; white arrows). By 3 d, FITC-latex remained abundant in the marginal zone phagocytes, but now DCs
(CD11c, not shown) were noted in the T cell areas (Fig. 4
F, arrow). When apoptotic (osmotically shocked) splenocytes were injected, uptake into CD8 and CD11c DCs
was prominent in the red pulp (Fig. 4, H and I, white arrows) and also noted in CD169 macrophages of the marginal zone (Fig. 4, H and I). Therefore, uptake of B cells
killed by NK cells in vivo is selectively observed in
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Figure 4. Localization of injected particulates in vivo. (A–C) Sections of spleen were examined 12 h after the injection of CFSE-labeled live allogeneic
B cells. In addition to green label from the CFSE-B cells, primarily in the white pulp (A), the sections were stained with CD11c (red DCs) and SER-4/
CD169 (blue marginal zone macrophages). B and C are enlarged views of several red CD11c DCs that have captured fragments of the injected B cells
(arrows) in the white pulp (CA, central artery) and red pulp. (D–F) Sections of spleen 1 h (D and E) and 3 d (F) after injection of FITC-latex, showing
strong labeling in marginal zone cells early on (MZ), and by day 3 (arrows), in T cell area DCs. Sections were stained with CD8 (red) and SER-4/CD169
(blue; D) or CD11c (red) and SER-4/CD169 (blue; E). Arrows and arrowheads indicate DCs and marginal zone macrophages engulfing FITC-Lx, respectively. (G and H) Sections of spleen, 1 h after injection of CFSE-labeled apoptotic B cells, were stained with either CD8 (G and H) or CD11c (I; red)
in combination with SER-4/CD169 (blue). In contrast with live B cells, very few CFSE-labeled apoptotic cells reached the T area, and most of them
were phagocytosed by marginal zone metallophils and red pulp DCs.
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cytic DCs from mice given PBS or syngeneic B cells (Fig. 6
B, top and middle rows), suggesting that a subset of MHC
class II rich DCs were either selectively phagocytic or were
expressing high MHC class II because of continuous processing of dying cells in the steady state. We then evaluated
presentation by different subsets of spleen cells of this same
I-Ab/I-E peptide complex to CD4 1H3 TCR transgenic
T cells, which have a similar specificity to the Y-Ae mAb
(32). Again CD8 DCs from either spleen or node selectively presented I-E from dying B cells to MHC class II–
restricted CD4 T cells (Fig. 6 C). Therefore, CD8 DCs
efficiently and selectively process dying allogeneic B cells in
situ including for presentation to CD4 T cells.
In Vitro, CD8 DCs Also Selectively Take Up and Present
Antigens from Dying Cells. The selective role of CD8
DCs in the uptake of dying cells could conceivably relate to
preferential access of dying cells to this subset in vivo. We
therefore performed experiments where apoptotic cells
were fed to CD11c selected DCs in vitro. Apoptotic syngeneic or allogeneic splenocytes were again efficiently captured by CD8 DCs, but not by CD8 DCs, from spleen,
subcutaneous lymph nodes, and liver (Fig. 7 A). The uptake
of apoptotic cells reached a plateau over 4–12 h (Fig. 7 B).
The percentage of phagocytic CD8 DCs increased with
increasing numbers of administered B cells, so that 60% of
the CD8 DCs showed phagocytic activity at the highest
dose of B cells tested (Fig. 7 C). When we examined the
cells by confocal microscopy, the DEC-205 DCs contained phagosomes with CFSE-labeled fragments (Fig. 7 D),
which is very similar to what we observed if we examined
DCs that had taken up dying cells in vivo (e.g., Fig. 4, B
and C). Both CD8 and CD8 DCs captured FITC latex
in vitro (Fig. 7 E), indicating that CD8 DCs were capable
of phagocytic activity. To verify that the selective uptake of
dying cells was associated with selective cross presentation
of antigen, we fed the DCs splenocytes shocked in the presence of OVA. The CD8 and CD8 DC subsets were then
added to OVA-specific, MHC class I–restricted, OT-I
TCR transgenic T cells. The CD8 DCs were markedly
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enriched in presenting activity (Fig. 7 F). Therefore CD8
DCs are specialized to take up and cross present dying cells.
In Vivo, CD8 DCs Selectively Capture Antigens from
Dying Cells for Presentation on Both MHC Class I and II Products. It has been reported that CD8 DCs in vivo selectively cross present OVA to OT-I T cells (19). Our findings suggest that this reflects selective uptake of dying
OVA-bearing splenocytes, rather than selective cross presenting function after uptake. To evaluate this, we injected
OVA-shocked splenocytes, isolated CD8 and CD8 DCs
(as well as lymphocytes), and tested if the APCs would
stimulate OT-I and also MHC class II–restricted OT-II T
cells. In fact, the CD8 DCs selectively presented cellassociated OVA to both CD8 and CD4 T cells (Fig. 8
A). As a positive control for the antigen-capturing activity
of CD8 DCs, we tested for presentation of soluble OVA
protein added to DC–T cell cocultures. Both CD8 and
CD8 DCs presented protein to MHC class II–restricted,
OT-II transgenic T cells but the presentation to OT-I was
weak, as expected for antigens administered in relatively
low doses as a soluble protein (Fig. 8 A, right part of each
panel). To determine if OVA protein injected in vivo
could be presented by both CD8 and CD8 DCs, we
used a high dose, 3 mg, intravenously. Both DC subsets
were able to stimulate MHC class I and class II–restricted
T cells (Fig. 8 B). We conclude that CD8 DCs selectively present antigens from dying cells on both MHC
class I and II products because of their selective endocytic
capacity for dying cells, but that CD8 DCs have the capacity to present the same protein when taken up by other
endocytic routes.
Expression of mRNA for Different Candidate Receptors for
Dying Cells. A number of receptors have been implicated
in the uptake of dying cells (33, 34), so we used RT-PCR
to search for these in CD8 and CD8 DCs as well as peritoneal macrophages. Two of these receptors, SR-AI and
C1qR, were restricted to macrophages, whereas others
(phosphatidyl serine receptor, 5A and B integrins, SR-BI,
CD14, CD68) were found in all three cell types. SR-AII,
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Figure 5. CFSE-labeled, cell lines and tumor cells are
selectively captured by CD8CD11c DCs in vivo. (A)
20  106 BaF3 tumor cells, induced to apoptose by 12 h of
culture in the absence of IL-3, were injected intravenously;
then splenic DCs were examined 2 h later for CFSEuptake (arrows) as in Fig. 1. The experiments were done
in parallel in wild type and DEC-205/ mice. Phagocytic
DCs in the CD11c population were 6.3% for C57BL/6
mice and 5.0% in DEC-205/ mice. (B) 5  106 EL-4
thymoma cells, untreated or induced to apoptose by heavy
irradiation (50 Gy) or by osmotic shock, were injected intravenously 2 h later, CD11c splenocytes were examined
for uptake of CFSE-labeled cells (arrows). CSFE-labeled
DCs were 0.04% in mice injected with untreated cells,
3.1% after osmotically shocked cells, and 5.15% after irradiated cells.

v, 3, mDC-SIGN, and CD23 were all more abundant in
CD8 versus CD8 DCs. Only CD36 was more abundant
in CD8 versus CD8 DCs. Therefore this preliminary
analysis only identified CD36 as a possible receptor that selectively guides dying cells to one DC subset, but further
analyses are required.
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Discussion
We have followed the uptake of dying cells in vivo, an
event that may be critical for the presentation of cell associated antigens in many clinical settings. We find that DCs
endocytose dying cells, by directly monitoring the capture
of fluorescein-labeled lymphocytes and various cell lines.
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Figure 6. Processing of allogeneic B cells in situ
to form MHC class II-peptide complexes. 20  106
live allogeneic (BALB/C) I-E B cells, or C57BL/6
syngeneic control B cells, were injected intravenously into C57BL/6 mice. (A) In vivo uptake of
apoptotic B cells (green) by MHC class II (blue)
and CD107b (red) DCs. Sorted CFSE-labeled
cells were placed on coverslips, fixed, and stained
with mAbs. (B) Phenotype of CD8 DCs 12 h after injecting live CFSE labeled allogeneic B cells.
Low density spleen cells, gated for both CD11c and
CD8 expression, were assessed for CFSE uptake (yaxis) and surface markers (x-axis; see text) including
Y-Ae an epitope formed by I-Ab presenting I-E
peptide. CFSE-labeled DCs by the injection of
syngeneic and allogeneic B cells were 1.38 and
28.1% in CD8 DCs, respectively. (C) At 12 h after injection of live syngeneic or allogeneic B cells,
low density spleen cells were separated into
CD11c DCs from the cells depleting CD3,
CD90, Gr-1, and B220-expressing cells with antiCD11c microbeads. The CD11c DCs from spleen
and lymph nodes were separated into CD8 and
CD8 subsets by sorting on a FACS Vantage™.
Graded doses were added to 2  105 CD4 1H3
TCR transgenic cells (reference 32) specific for I-Ab
presenting I-E peptide, kindly provided by Drs. C.
Viret and C. Janeway of Yale Medical School,
New Haven, CT. Proliferation ([3H]thymidine uptake) was measured at 27–40 h.

Uptake however takes place primarily in the CD8 subset
of DCs. Likewise, when experiments are performed in
vitro under more easily controlled conditions, the majority
of the CD8 DCs selectively express phagocytic activity
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for dying cells. We also find that the selective presenting
activity of CD8 DCs extends to both MHC class I and II
products, whereas both CD8 and CD8 DC subsets are
able to present soluble protein captured in vivo on MHC
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Figure 7. CD8 DCs selectively capture and present dying cells in vitro. (A)
CD11c DCs were selected were
stained with PE-CD8 for spleen and
subcutaneous lymph nodes and PECD11b for liver. In flat-bottomed microtest wells, 105 DCs were cocultured
with 3  105 CFSE-labeled apoptotic
(osmotic shock) B cells for 4 h at 4 C or
37 C. Residual B cells were gated from
these FACS® plots by CD19 labeling (biotin-CD19 and avidine-CyChrome®).
(B) Kinetics of uptake (FACS® assay) of
osmotically shocked apoptotic syngeneic
and allogeneic B cells by DCs from
spleen, subcutaneous lymph nodes, and
liver. The percentage of CFSE-labeled
DCs were shown in the respective subsets. (C) Effect of increasing dose of B
cells on the frequency of DCs phagocytic for apoptotic B cells. CFSE-labeled
DCs were assessed 4h after coculture as
described in panel A. (D) In vitro uptake
of apoptotic B cells (green) by MHC
class II (blue) and DEC-205 (red)
DCs. (E) Uptake of FITC latex by DCs
from the three different tissues we have
studied, showing uptake at 37 C (right
side of each panel) by both CD8 and
CD8 DCs. The percentage of FITCLx CD8 and CD8 DCs and FITCLx CD8 and CD8 DCs were 33.2,
64.8, 0.7, and 1.3 at 4 C and 28.5, 54.3,
5.3, and 11.9 at 37 C for spleen, 39.4,
52.5, 1.2, and 1.9 at 4 C and 32.7, 46.2,
7.6, and 13.5 at 37 C for subcutaneous
lymph nodes, and those of FITC-Lx
CD11b and CD11b DCs and FITCLxCD11b and CD11b DCs were
20.5, 78.0, 0.3, 1.2 at 4 C and 14.1,
60.2, 6.2, and 19.5 at 37 C for liver. (F)
Selective presentation by CD8 DCs of
OVA from apoptotic splenocytes. DCs
were selected from CD3, Gr-1, and
B220-negative low density splenocytes
sequentially with anti-CD8 and antiCD11c microbeads® and cultured for 4 h
with splenocytes (1 DC:3 spleen cells) loaded with 10 mg/ml OVA during osmotic shock.
After the culture, the both subsets of DCs were again stained with FITC-anti-CD11c and
anti-FITC microbeads®, and the DCs were selected by MACS columns to avoid contamination of dead cells. Both CD8 and CD8 subsets were used in graded doses to present
antigen to 2  105 purified OT-I T cells in flat bottomed microtest wells. [3H]thymidine
uptake was measured at 38–50 h.

class I and II. These results likely explain the fact that
CD8 DCs selectively cross present cell-associated antigens
(19; Fig. 8). Our findings provide a means for experimentally loading DCs in situ with antigens derived from self, allogeneic, or malignant cells (Figs. 1–5).
The capacity of CD8 DCs to take up dying cells is efficient. In the case of allogeneic B cells as substrate, a substantial proportion of the DCs can be directly visualized
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with phagocytosed dying cells by FACS® and by immunofluorescence microscopy in section (Fig. 4 B). If DCs are
isolated after uptake of dying cells in vivo (not shown) or
in vitro (Fig. 7 D), the cells contain several intracellular
CFSE-labeled phagosomes. Furthermore, most of the
phagocytic DCs can be shown to be forming MHC–peptide complexes after processing of a membrane protein from
the dying cells (Fig. 6 B). Uptake of osmotically shocked

Uptake of Dying Cells by CD8 DCs In Situ

Downloaded from http://rupress.org/jem/article-pdf/195/10/1289/984051/jem195101289.pdf by Rockefeller University user on 11 August 2020

Figure 8. CD8 DCs selectively capture dying cells in
vivo for presentation on MHC class I and II products. (A)
OVA presentation from TAP/ splenocytes, osmotically
shocked in PBS or 10 mg/ml OVA (x-axis) before injecting 20  106 cells intravenously per mouse. 4 h later,
spleen cell suspensions were prepared and DCs partially
enriched by flotation in dense BSA solution (reference 22).
Subsets of APCs were isolated by the following sequence
using antibody-coated magnetic beads: mixtures of CD5
and CD19 cells (B and T), CD8 cells (DCs), and
CD11c cells (CD8 DCs). Cells were added in graded
doses to 2  105 purified OT-I or OT-II cells in flatbottomed microtest wells. Proliferation was measured at
38–50 h, with the data shown for the top dose of APCs
(3  104 for DCs and 2.5  105 for lymphocytes). In parallel, cells from the PBS-injected mice were also used to
present OVA protein, at a dose of 30 g/ml continuously
in the DC–T cell cocultures. (B) Both CD8 and CD8
DCs can present soluble OVA via the exogenous pathway
to MHC class I. Mice were injected intravenously with 3
mg of OVA protein. At the indicated times, subsets of
APCs were isolated as in panel A and used (104 DCs and
3  105 lymphocytes) to stimulate OT-I (1.4  105) and
OT-II (2  105) cells. [3H]thymidine uptake was measured
at 38–50 h. (C) 20  106 EL-4 thymoma cells loaded with
OVA with 10 mg/ml OVA during osmotic shock were injected. CD8 and CD8 CD11c DCs and CD11c cells
were prepared by MACS columns 8 h later and cultured
with 2  105 OT-I T cells in 96-well flat bottomed microtest plates in triplicates. 3H-TdR uptake between 36–
48 h was measured. Control mice were injected EL-4 cells
treated by the same way in the absence of OVA. Purities of
CD8 and CD8 DCs from the mice injected with OVAloaded EL-4 cells were 91.4 and 90.3%, respectively. (D)
TAP-dependent presentation of OVA by DCs to specific
CD8 OT-I T cells. CD11c DCs were obtained from
the TAP/ and littermate control mice that had been injected intravenously with 15  106 OVA-loaded or unloaded EL-4 cells 7.5 h before. Graded doses of DCs were
cultured with 1  105 OT-I T cells in round-bottomed
microculture plates for 48 h. 3H-TdR uptake for the last
8 h was determined.
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comparably efficient to wild-type in taking up injected
cells (Fig. 5). An analysis of mRNA expression for several
candidate phagocytic receptors for dying cells (33, 34) only
identified CD36 as being expressed more abundantly in
CD8 DCs. Most other receptors were expressed similarly
in both DC subsets, or were more abundant in CD8 DCs
(Fig. 9).
It is of interest that several DC subsets are proving to have
distinct receptors for endocytosis. These include BDCA-2
on plasmacytoid DCs (42), Langerin on Langerhans cells
(43), DC-SIGN (44) and asialoglycoprotein receptor on
monocyte-derived DCs (45). This may allow subsets of
DCs to present select antigens and microbes; in addition
these subsets can express distinct toll-like receptors (46, 47).
The selective uptake of dying cells, which is evident in vivo
and at the single cell level, represents one of the most dramatic known differences in the function of CD8 and
CD8 DC subsets in mouse spleen and lymph node.
It is proposed (48–50) that the uptake of antigens by immature DCs in the steady-state will lead to the induction of
tolerance to those peptides that are successfully presented,
whereas maturation stimuli are required to make DCs immunogenic for effector and memory cell formation. Evi-

Figure 9. RT-PCR analysis for the expression of receptors that may be
involved in engulfment of dying cells. Purified DC subsets from spleen,
obtained by FACS®-sorting, were subject to the assay and compared with
peritoneal macrophages.
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cells is also readily observed in DCs in splenic red pulp,
and by some macrophages in the marginal zone of tissue
sections of spleen (Fig. 4, G–I), as long as one looks within
1 h after injection of the apoptotic cells. However,
sialoadhesin (CD169) large phagocytic cells are difficult
to liberate into a cell suspension. In contrast, marginal zone
and red pulp macrophages do not appear to participate in
the clearance of live allogeneic B cells, killed by NK cells
(Fig. 4, A–C).
A number of functional differences have been reported
in the function of CD8 and CD8 DCs from mice.
Shortman et al. first noted that CD8 DCs are less active in
inducing T cell proliferation and cytokine production (35–
37). In contrast, when DC subsets are pulsed with antigen
and matured ex vivo, and then reinjected into mice, CD8
DCs preferentially stimulate strong Th1 responses (38, 39).
This paper describes a new functional distinction of the
CD8 subset that can be documented in situ and in culture. These DCs selectively take up dying cells under several conditions. The first are syngeneic splenocytes rendered apoptotic by osmotic shock before injection, a
procedure commonly used to study delivery of cell-associated proteins into mice (16–18). The second are intact allogeneic cells that are likely killed in vivo by asialoGM1
NK cells. The third are cell lines and tumor cells induced
to apoptose by various means. The highest frequencies of
phagocytic CD8 DCs in vivo are observed with allogeneic cells, with 20–30% of the DCs showing uptake of the
injected CFSE-labeled allogeneic B cells. These findings
with CD8 DCs in mice parallel the findings of Huang et
al. who have reported that the subset of CD4 DCs in rat
mesenteric lymph selectively carries apoptotic fragments of
intestinal epithelial cells (40). CD8 is not expressed by rat
DCs, but the phagocytic CD8 mouse DCs are CD4
(while CD8 DCs are to a major extent CD4 [26]), paralleling the data of Huang et al.
We suspect that the selective capacity of CD8 DCs to
cross present dying cells on MHC class I is controlled primarily at the level of specific endocytic receptors, rather
than subsequent processing. Both subsets of DCs were able
to present soluble OVA to MHC class I–restricted T cells
(Fig. 8 B), which is distinct from the report of Pooley et al.
(41). They found that CD8 DCs selectively presented
soluble OVA on MHC class I, while CD8 DCs present
OVA on MHC class II. Perhaps there are quantitative differences that we were unable to detect with our particular
preparation of OVA; also we did not add IL-2 to our T
cell assays. CD8 DCs do have phagocytic activity, as we
confirmed that both CD8 and CD8 DCs take up FITC
latex (20). CD8 DCs also selective take up and present
dying cells in vitro, where access of particles to both
CD8CD8 DCs is ensured. Therefore CD8 DCs are
phagocytic and can present antigens on both MHC class I
and II; however, this DC subset seems to ignore dying
cells. We hypothesize that CD8 DCs selectively express a
receptor for apoptotic cells. This receptor is not the DEC205 receptor, at least exclusively. DEC-205 is abundant on
CD8 DCs (26, 27), but DEC-205 knockout mice are

dence for this has recently been obtained in studies of the
presentation of an antigenic peptide delivered selectively to
DCs in situ via a monoclonal anti–DEC-205 antibody (49).
There is evidence that certain necrotic cells, but not apoptotic cells, are able to induce maturation of DCs in culture
(51, 52), with the release of heat shock proteins being a relevant stimulus (53, 54). Experiments to test the tolerizing
and immunizing properties of cell-associated antigens, injected under steady-state and DC maturation conditions,
are underway using the methods described here to facilitate
the uptake of dying cells by DCs in situ.
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